

Alligator Bioscience Q4 2024 - Can the Rights Issue Fund Alligator to a Deal?

Redeye comments on Alligator Bioscience's Q4 report and the rights issue, which was subscribed to 54%. This means no guarantee commitments will be utilised. Mitazalimab is close to reaching phase III readiness. The key element missing is funding, which has to come from a partner.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Alligator Bioscience Q4 2024 - Can the Rights Issue Fund Alligator to a Deal?](#)